Analysts Set Millendo Therapeutics Inc (NASDAQ:MLND) PT at $25.29

Shares of Millendo Therapeutics Inc (NASDAQ:MLND) have earned a consensus recommendation of “Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $25.14.

Several equities research analysts have issued reports on MLND shares. Wedbush began coverage on shares of Millendo Therapeutics in a research report on Thursday, July 18th. They issued an “outperform” rating and a $24.00 price objective for the company. Oppenheimer cut their price target on shares of Millendo Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday. ValuEngine upgraded shares of Millendo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Citigroup began coverage on shares of Millendo Therapeutics in a report on Monday, July 15th. They issued an “outperform” rating and a $26.00 price objective on the stock. Finally, CIBC began coverage on shares of Millendo Therapeutics in a report on Tuesday, July 16th. They set an “outperform” rating and a $26.00 price target on the stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Millendo Therapeutics during the fourth quarter worth about $203,000. Geode Capital Management LLC acquired a new stake in Millendo Therapeutics during the 4th quarter worth about $113,000. Private Advisors LLC raised its stake in shares of Millendo Therapeutics by 9.1% during the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after purchasing an additional 1,279 shares in the last quarter. Strs Ohio purchased a new stake in shares of Millendo Therapeutics during the 2nd quarter worth about $28,000. Finally, Wells Fargo & Company MN raised its stake in shares of Millendo Therapeutics by 1,830.5% during the 2nd quarter. Wells Fargo & Company MN now owns 14,479 shares of the company’s stock worth $168,000 after purchasing an additional 13,729 shares in the last quarter. Hedge funds and other institutional investors own 44.03% of the company’s stock.



MLND stock traded down $0.30 on Friday, hitting $7.20. The company had a trading volume of 999 shares, compared to its average volume of 37,651. Millendo Therapeutics has a 12-month low of $6.77 and a 12-month high of $17.34. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average of $10.46. The company has a market capitalization of $100.93 million, a PE ratio of -0.41 and a beta of 2.64.

Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.07. Analysts anticipate that Millendo Therapeutics will post -3.32 earnings per share for the current year.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Story: How is the Producer Price Index calculated?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.